There’s no denying the popularity of weight-loss drugs in the United States, with one in eight adults relying on GLP-1s to shed pounds or treat a chronic condition, according to a November survey by health policy organization KFF.
The GLP-1 industry is generating billions in revenue - and growing. Medications, like Ozempic and Wegovy, raked in more than $31 billion in revenue for Danish pharmaceutical company Novo Nordisk in 2024, accounting for meaningful chunk of Denmark’s GDP, Reuters reports.
